Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 273-282

  Nosheny, Rachel L ^a   Insel, Philip S ^a   Truran, Diana ^a   Schuff, Norbert ^a   Jack, Clifford R ^b   Aisen, Paul S ^c   Shaw, Leslie M ^d   Trojanowski, John Q ^d   Weiner, Michael W ^a,e  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Huntington Research Institute   (United States)

Author keywords

Alzheimer's disease; Hippocampal atrophy rate; Longitudinal study; Normal aging; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGE DISTRIBUTION; AGED; AGING; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; FEMALE; HIPPOCAMPAL ATROPHY RATE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; WHITE MATTER LESION; ATROPHY; DIFFUSION WEIGHTED IMAGING; HIPPOCAMPUS; METABOLISM; ORGAN SIZE; PATHOLOGY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; ATROPHY; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HIPPOCAMPUS; HUMANS; LINEAR MODELS; MALE; MILD COGNITIVE IMPAIRMENT; ORGAN SIZE;

EID: 84920495244     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.036     Document Type: Article

References (49)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
2. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., Fischl B., Greve D.N., Marshall G.A., Salloway S., Marks D., Buckner R.L., Sperling R.A., Johnson K.A. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann. Neurol. 2011, 69:1032-1042.
3. Brickman A.M., Schupf N., Manly J.J., Luchsinger J.A., Andrews H., Tang M.X., Reitz C., Small S.A., Mayeux R., DeCarli C., Brown T.R. Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch. Neurol. 2008, 65:1053-1061.
4. Cardenas V.A., Du A.T., Hardin D., Ezekiel F., Weber P., Jagust W.J., Chui H.C., Schuff N., Weiner M.W. Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia. Neurobiol. Aging 2003, 24:537-544.
5. Carmichael O., Schwarz C., Drucker D., Fletcher E., Harvey D., Beckett L., Jack C.R., Weiner M., DeCarli C. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 2010, 67:1370-1378. Alzheimer's Disease Neuroimaging Initiative.
6. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman E.P., Zehntner S.P., Skovronsky D.M., Reiman E.M., Zehntner S.P., Skovronsky D.M. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283. for the AV45-A07 Study Group.
7. Constans J.M., Meyerhoff D.J., Gerson J., MacKay S., Norman D., Fein G., Weiner M.W. H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia. Radiology 1995, 197:517-523.
8. Cowell P.E., Turetsky B.I., Gur R.C., Grossman R.I., Shtasel D.L., Gur R.E. Sex differences in aging of the human frontal and temporal lobes. J.Neurosci. 1994, 14:4748-4755.
9. Crivello F., Lemaitre H., Dufouil C., Grassiot B., Delcroix N., Tzourio-Mazoyer N., Tzourio C., Mazoyer B. Effects of ApoE-epsilon4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons. Neuroimage 2010, 53:1064-1069.
10. Dickerson B.C., Stoub T.R., Shah R.C., Sperling R.A., Killiany R.J., Albert M.S., Hyman B.T., Blacker D., Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76:1395-1402.
11. Du A.T., Schuff N., Chao L.L., Kornak J., Jagust W.J., Kramer J.H., Reed B.R., Miller B.L., Norman D., Chui H.C., Weiner M.W. Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol. Aging 2006, 27:733-740.
12. Du A.T., Schuff N., Zhu X.P., Jagust W.J., Miller B.L., Reed B.R., Kramer J.H., Mungas D., Yaffe K., Chui H.C., Weiner M.W. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology 2003, 60:481-486.
13. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
14. Farias S.T., Mungas D., Reed B., Carmichael O., Beckett L., Harvey D., Olichney J., Simmons A., Decarli C. Maximal brain size remains an important predictor of cognition in old age, independent of current brain pathology. Neurobiol. Aging 2012, 33:1758-1768.
15. Fischl B., Salat D.H., Busa E., Albert M., Dieterich M., Haselgrove C., van der Kouwe A., Killiany R., Kennedy D., Klaveness S., Montillo A., Makris N., Rosen B., Dale A.M. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
16. Fischl B., van der Kouwe A., Destrieux C., Halgren E., Segonne F., Salat D.H., Busa E., Seidman L.J., Goldstein J., Kennedy D., Caviness V., Makris N., Rosen B., Dale A.M. Automatically parcellating the human cerebral cortex. Cereb. Cortex 2004, 14:11-22.
17. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Blennow K., Brewer J.B., Dale A.M. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb. Cortex 2010, 20:2069-2079.
18. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Brewer J.B., Dale A.M. One-year brain atrophy evident in healthy aging. J.Neurosci. 2009, 29:15223-15231.
19. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
20. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., Foster N.L., Jack C.R., Galasko D.R., Doody R., Kaye J., Sano M., Mohs R., Gauthier S., Kim H.T., Jin S., Schultz A.N., Schafer K., Mulnard R., van Dyck C.H., Mintzer J., Zamrini E.Y., Cahn-Weiner D., Thal L.J. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch. Neurol. 2004, 61:59-66. for the Alzheimer's Disease Cooperative Study.
21. Holland D., Desikan R.S., Dale A.M., McEvoy L.K. Rates of decline in Alzheimer disease decrease with age. PLoS One 2012, 7:e42325. for the Alzheimer's Disease Neuroimaging Initiative.
22. Holland D., McEvoy L.K., Desikan R.S., Dale A.M. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One 2012, 7:e47739. for the Alzheimer's Disease Neuroimaging Initiative.
23. Honea R.A., Swerdlow R.H., Vidoni E.D., Burns J.M. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
24. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., Whitwel J.L., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J.Magn. Reson. Imaging 2008, 27:685-691.
25. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
26. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
27. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
28. Jack C.R., Petersen R.C., Xu Y.C., Waring S.C., O'Brien P.C., Tangalos E.G., Smith G.E., Ivnik R.J., Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49:786-794.
29. Jagust W.J., Zheng L., Harvey D.J., Mack W.J., Vinters H.V., Weiner M.W., Ellis W.G., Zarow C., Mungas D., Reed B.R., Kramer J.H., Schuff N., DeCarli C., Chui H.C. Neuropathological basis of magnetic resonance images in aging and dementia. Ann. Neurol. 2008, 63:72-80.
30. Johnson K.A., Sperling R.A., Gidicsin C.M., Carmasin J.S., Maye J.E., Coleman R.E., Reiman E.M., Sabbagh M.N., Sadowsky C.H., Fleisher A.S., Murali Doraiswamy P., Carpenter A.P., Clark C.M., Joshi A.D., Lu M., Grundman M., Mintun M.A., Pontecorvo M.J., Skovronsky D.M., group A.A.s. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013, 9:S72-S83.
31. Joshi A.D., Pontecorvo M.J., Clark C.M., Carpenter A.P., Jennings D.L., Sadowsky C.H., Adler L.P., Kovnat K.D., Seibyl J.P., Arora A., Saha K., Burns J.D., Lowrey M.J., Mintun M.A., Skovronsky D.M. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J.Nucl. Med. 2012, 53:378-384. the Florbetapir F 18 Study Investigators.
32. Kosik K.S., Joachim C.L., Selkoe D.J. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1986, 83:4044-4048.
33. Mormino E.C., Brandel M.G., Madison C.M., Rabinovici G.D., Marks S., Baker S.L., Jagust W.J. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012, 59:1152-1160.
34. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
35. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Toga A.W., Jack C.R., Schuff N., Weiner M.W., Thompson P.M. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009, 45:S3-S15. the Alzheimer's Disease Neuroimaging Initiative.
36. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009, 66:1469-1475.
37. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 2001, 58:397-405.
38. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
39. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
40. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
41. Schott J.M., Bartlett J.W., Fox N.C., Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann. Neurol. 2010, 68:825-834.
42. Schuff N., Tosun D., Insel P.S., Chiang G.C., Truran D., Aisen P.S., Jack C.R., Weiner M.W. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol. Aging 2012, 33:845-855. Alzheimer's Disease Neuroimaging Initiative.
43. Seab J.P., Jagust W.J., Wong S.T., Roos M.S., Reed B.R., Budinger T.F. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn. Reson. Med. 1988, 8:200-208.
44. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
45. Sowell E.R., Peterson B.S., Kan E., Woods R.P., Yoshii J., Bansal R., Xu D., Zhu H., Thompson P.M., Toga A.W. Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb. Cortex 2007, 17:1550-1560.
46. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
47. Tosun D., Schuff N., Truran-Sacrey D., Shaw L.M., Trojanowski J.Q., Aisen P., Peterson R., Weiner M.W. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol. Aging 2010, 31:1340-1354.
48. Weigand S.D., Vemuri P., Wiste H.J., Senjem M.L., Pankratz V.S., Aisen P.S., Weiner M.W., Petersen R.C., Shaw L.M., Trojanowski J.Q., Knopman D.S., Jack C.R. Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement. 2011, 7:133-141. Alzheimer's Disease Neuroimaging Initiative.
49. Whitwell J.L., Wiste H.J., Weigand S.D., Rocca W.A., Knopman D.S., Roberts R.O., Boeve B.F., Petersen R.C., Jack C.R. Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. Arch. Neurol. 2012, 69:614-622.